India, Feb. 9 -- image credit- freepik

Pandorum Technologies, a Bengaluru-based biotechnology company pioneering programmable regenerative medicine, with operations in India and the United States, has announced the closing of a $18 million in Series B financing round, to advance the clinical development of its disease-modifying, tunable, exosome-based therapies, including Kuragenx, while scaling global manufacturing and expanding operations across the US, Japan, and the Middle East.

The round was led by Protons Corporate, with participation from Galentic Pharma, marquee investor Ashish Kacholia, Noblevast Advisory and Avinya Fund, Burman Family and others.Bandana Kankani, advisor and investor at Pandorum, had guided the transaction, opt...